Provided by Tiger Trade Technology Pte. Ltd.

AKESO

103.400
+1.7001.67%
Volume:166.00K
Turnover:17.06M
Market Cap:95.23B
PE:-171.03
High:103.400
Open:103.000
Low:101.700
Close:101.700
52wk High:179.000
52wk Low:55.650
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:0.96
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.605
ROE:-14.61%
ROA:-4.41%
PB:13.10
PE(LYR):-171.03
PS:33.57

Loading ...

Akeso Reports Promising Phase III Results for Ivonescimab in Advanced Biliary Tract Cancer

Reuters
·
Feb 06

Akeso startet Phase-III-Studie mit Ivonescimab zur Erstlinienbehandlung von fortgeschrittenem Gallengangskrebs

Reuters
·
Feb 06

Akeso, Inc. (09926) Announces Monthly Return for January 2026

Bulletin Express
·
Feb 05

BRIEF-Akeso Granted Exclusive Commercialization Rights For Ebronucimab Injection To Jumpcan Pharmaceutical

Reuters
·
Feb 03

Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit

MT Newswires Live
·
Feb 03

Akeso (9926) and JumpCan (600566.SS) Sign Exclusive Commercialization Agreement for 伊喜寧®

Bulletin Express
·
Feb 03

AKESO (09926) Grants Exclusive Commercialization Rights for Yixining® to Jumpcan Pharmaceutical

Stock News
·
Feb 03

Akeso - Akeso Granted Exclusive Commercialization Rights for Ebronucimab Injection to Jumpcan Pharmaceutical

THOMSON REUTERS
·
Feb 03

Akeso - to Receive RMB80 Mln License Fee and RMB10 Mln Milestones

THOMSON REUTERS
·
Feb 03

Akeso Updates Contract Manufacturing Arrangement with Supplemental Agreement Expiry Set for 2039

Reuters
·
Jan 26

Gumokimab sNDA Acceptance for Ankylosing Spondylitis Could Be A Game Changer For Akeso (SEHK:9926)

Simply Wall St.
·
Jan 24

Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%

Deep News
·
Jan 23

AKESO Surges Over 5% in Early Trading as Second Indication for Self-Developed Gumokimab Receives NDA Acceptance

Deep News
·
Jan 23

Akeso (SEHK:9926) Valuation Check After Recent Share Price Pullback

Simply Wall St.
·
Jan 22

Akeso sNDA for Gumokimab in Ankylosing Spondylitis Accepted for NMPA Review

Reuters
·
Jan 19

Akeso Announces Nmpa Acceptance of Second Nda for Gumokimab (Il-17a Inhibitor) in Active Ankylosing Spondylitis

THOMSON REUTERS
·
Jan 19

CICC Hong Kong Stock Connect and Hang Seng Index Adjustment Preview: Zijin Gold Intl (02259) Among Potential Hang Seng Index Additions; 44 Companies Expected to Enter Stock Connect

Stock News
·
Jan 19

Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study

Reuters
·
Jan 14

Zhutong Hong Kong Stock Connect Active Trading | January 13

Stock News
·
Jan 13

Hong Kong Stock Concept Tracking | China's NMPA Optimizes Review and Approval Process for Clinically Urgent Overseas Drugs, Sustaining High Growth Momentum in Innovative Medicines (Including Concept Stocks)

Stock News
·
Jan 08